Treatment for chronic myeloid leukaemia (CML)

If you have high white blood cell counts or worrying symptoms, your doctors might start treatment before all your test results come back. This is likely to be a course of tablets called hydroxycarbamide (also known as hydroxyurea). This is a type of chemotherapy that helps lower your white blood cell count.

We have separate information about hydroxycarbamide.

Once your blood counts improve, your haematology team usually reduce the dose before stopping it completely.

The treatment you have depends on the phase of your CML.

• If your CML is in the chronic phase, the usual treatment is a type of targeted therapy called a TKI tyrosine kinase inhibitor (TKI).
• If your CML is in the blast phase, your doctors might suggest adding chemotherapy to your TKI. They could advise a stem cell transplant as well.

Depending on your circumstances, your haematology team might suggest other treatments. They will explain what they recommend for you.

TKIs

Tyrosine kinase inhibitors (TKIs) are a type of targeted therapy. They block an abnormal protein called BCR-ABL, which is a type of tyrosine kinase. This abnormal protein is present in people with CML. It encourages the blood-forming cells in your bone marrow to make too many white blood cells. Blocking the protein helps stop the leukaemia cells from multiplying.

TKIs are tablets that you take by mouth. They are generally highly effective at keeping CML under control. Each TKI has a different profile and might cause different side effects. We have separate information on each of the TKIs used to treat CML:

• Imatinib
• Nilotinib
• Dasatinib
• Bosutinib
• Ponatinib
• Asciminib

Your doctors will suggest the most suitable TKI for you based on:

• Your personal characteristics such as your age, any other medical conditions you have, and your treatment preference
• Features of your CML, like its phase and the exact genetic changes in your leukaemia cells
• How you’ve responded to any previous treatment you have had

Chemotherapy

You might be offered chemotherapy as well as a TKI if your CML is in the blast phase. Different combinations of chemotherapy medicines may be used. Your haematology team will tell you what they recommend. They will explain what the treatment is, how you have it, and what side effects that you might get.

• Macmillan Cancer Support have more information about particular chemotherapy combinations.

Rarely, some people have leukaemia cells in the central nervous system. If this is the case, you may also need a course of chemotherapy directly into the fluid surrounding your brain and spinal cord. This is called intrathecal chemotherapy.

Stem cell transplant

A stem cell transplant involves having high-dose chemotherapy to kill blood-forming stem cells in your bone marrow. These are then replaced by healthy stem cells from a matched donor.

A stem cell transplant is very intensive. It is only suitable for people who are fit enough to have it. Your haematology team might suggest a stem cell transplant if your CML is in the blast phase. They might also consider it if you’ve already had treatment with several different TKIs.

Your haematology team will let you know early on if a stem cell transplant is an option for you. They will discuss it with you and explain its benefits and risks.

We have separate information about stem cell transplants.

Supportive care

During your treatment and afterwards, you might also need medicine to prevent or treat symptoms or side effects. This is called supportive care. It does not treat your CML itself, but it helps you feel better.

As well as medicines to help you, supportive care can include:

• Psychological support
• Support with exercise or physiotherapy
• Social support
• Spiritual wellbeing such as mindfulness

Your haematology team should talk to you to find out what support they can offer you.

If your treatment is not successful, your haematology team will suggest changing to a different treatment. This may happen if:

• Your CML does not respond to the treatment
• Your CML responds to the treatment at first but then stops responding
• You have side effects that are difficult to manage

If your treatment is not successful, your haematology team will suggest the most suitable next treatment based on your individual circumstances. For most people, the usual second treatment is a different TKI. If second-line TKI treatment is not successful, the usual next treatment is another TKI.

TKIs all work in slightly different ways and have different side effects. Some are effective against particular gene changes. If one TKI is not successful, a different TKI may be.

TKIs are effective for most people, but if they are not suitable for you, your haematology team will discuss other treatment options This could include a stem cell transplant or supportive care.

We have more information about second- and later-line treatment for CML.

Sources we used to develop this information

Annunziata M, Bonifacio M, Breccia M, Castagnetti F, Gozzini A, Iurlo A, et al. Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia. Front Oncol 2020;10:883.

Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Journal of clinical oncology. 2009 Dec 12;27(35):6041.

Bonifacio M, Stagno F, Scaffidi L, Krampera M, Di Raimondo F. Management of chronic myeloid leukaemia in advanced phase. Front Oncol 2019;9: Art 1132.

Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 2018;17(1):58.

Garcia-Gutierrez V, Hernandez-Boluda JC. Tyrosine kinase inhibitors available for chronic myeloid leukaemia: Efficacy and safety. Front Oncol 2019;9:Art 603.

Healey MA, Allendorf DJ, Borate U, Madan A. CNS Involvement in a Patient with Chronic Myeloid Leukemia. Case Rep Hematol 2021;2021:8891376.

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020;34(4):966-984.

Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, et al; ESMO Guidelines Committee. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(suppl_4):iv41-iv51.

Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukaemia after ABL kinase inhibitor failure. N Engl J Med 2019; 381:2315-2326.

Incyte Biosciences UK Ltd. Ponatinib 15 mg tablets. Summary of Product Characteristics. July 2022. Available at: https://www.medicines.org.uk/emc/product/1212/smpc [Last accessed 9/11/23]

Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk 2015;15(6):323-334.

Janssen L, Blijlevens NMA, Drissen MMCM, Bakker EA, Nuijten MAH, Janssen JJWM, et al. Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity. Haematologica 2021;106(7):1876-1882.

Medac. Hydroxycarbamide 500 mg capsules. Summary of Product Characteristics. February 2023. Available at: https://www.medicines.org.uk/emc/product/254/smpc [Last accessed 07/11/2023]

Mylan. Dasatinib 100 mg tablet. Summary of Product Characteristics. 25 July 2023. Available at: https://www.medicines.org.uk/emc/product/14399/smpc. [Last accessed: 9/11/23]

National Institute for Health and Care Excellence (NICE). Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors. Technology appraisal guidance [TA813]. Published: 03 August 2022. Available at:  https://www.nice.org.uk/guidance/ta813

National Institute for Health and Care Excellence (NICE). Bosutinib for previously treated chronic myeloid leukaemia. Technology appraisal guidance [TA401] Published: 24 August 2016. Available at: https://www.nice.org.uk/guidance/ta401

National Institute for Health and Care Excellence (NICE). Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia. Technology appraisal guidance [TA425]. Published: 21 December 2016. Available at: https://www.nice.org.uk/guidance/ta425

National Institute for Health and Care Excellence (NICE). Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia. Technology appraisal guidance [TA426] Published: 21 December 2016. Available at: https://www.nice.org.uk/guidance/ta426

National Institute for Health and Care Excellence (NICE). Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia. Technology appraisal guidance [TA451] Published: 28 June 2017. Available at: https://www.nice.org.uk/guidance/ta451 [Last accessed 9/11/23]

Novartis Pharmaceuticals. Imatinib 100 mg tablets. Summary of Product Characteristics. October 2023. Available at: https://www.medicines.org.uk/emc/product/7779/smpc [Last accessed 9/11/23]

Novartis Pharmaceuticals. Nilotinib 150 mg capsules. Summary of Product Characteristics. October 2023. Available at: https://www.medicines.org.uk/emc/product/5852/smpc [Last accessed 9/11/23]]

Pfizer Limited. Bosutinib 100 mg tablet. Summary of Product Characteristics. 15 May 2023. Available at: https://www.medicines.org.uk/emc/product/3147/smpc. [Last accessed: 9/11/23]

Radivoyevitch T, Jankovic GM, Tiu RV, Saunthararajah Y, Jackson RC, Hlatky LR, et al. Sex differences in the incidence of chronic myeloid leukemia. Radiat Environ Biophys 2014;53(1):55-63.

Saglio G, Gale RP. Prospects for achieving treatment-free remission in chronic myeloid leukaemia. Br J Haematol 2020;190(3):318-327.

Smith G, Apperley J, Milojkovic D, Cross NCP, Foroni L, Byrne J, et al; British Society for Haematology. A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol 2020;191(2):171-193. Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukaemia: the paradigm of targeting oncogenic tyrosine kinase signalling and counteracting resistance for successful cancer therapy. Mol Cancer 2018;17(1):49

Swerdlow SH, Campo E, Harris NL, Jaffa ES, Pileri SA, Stein H, Thiele J (Eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). IARC: Lyon 2017.

Westerweel PE, Te Boekhorst PAW, Levin MD, Cornelissen JJ. New approaches and treatment combinations for the management of chronic myeloid leukaemia. Front Oncol 2019;9: Art 665.